Boer Daniel Anton De Purchases 150,000 Shares of ProQR Therapeutics (NASDAQ:PRQR) Stock

ProQR Therapeutics N.V. (NASDAQ:PRQR) CEO Boer Daniel Anton De bought 150,000 shares of the stock in a transaction that occurred on Thursday, July 9th. The stock was acquired at an average price of $1.74 per share, for a total transaction of $261,000.00. Following the acquisition, the chief executive officer directly owned 300,000 shares in the company, valued at $522,000. The trade was a 100.00% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink.

Boer Daniel Anton De also recently made the following trade(s):

• On Tuesday, July 7th, Boer Daniel Anton De purchased 150,000 shares of ProQR Therapeutics stock. The shares were bought at an average price of $1.59 per share, with a total value of $238,500.00.

ProQR Therapeutics Stock Performance

PRQR stock opened at $1.70 on Wednesday. The business has a 50-day simple moving average of $1.62 and a two-hundred day simple moving average of $1.67. The company has a market capitalization of $179.11 million, a P/E ratio of -3.40 and a beta of 0.04. ProQR Therapeutics N.V. has a 52-week low of $1.33 and a 52-week high of $3.10.

ProQR Therapeutics (NASDAQ:PRQR) last issued its quarterly earnings data on Tuesday, May 12th. The biopharmaceutical company reported ($0.15) EPS for the quarter, hitting the consensus estimate of ($0.15). ProQR Therapeutics had a negative return on equity of 84.87% and a negative net margin of 331.33%.The firm had revenue of $2.35 million during the quarter, compared to the consensus estimate of $5.19 million. As a group, sell-side analysts forecast that ProQR Therapeutics N.V. will post -0.52 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on PRQR shares. Chardan Capital dropped their price objective on ProQR Therapeutics from $4.00 to $3.00 and set a “buy” rating on the stock in a research note on Friday, June 26th. Citigroup reiterated a “market outperform” rating on shares of ProQR Therapeutics in a research note on Wednesday, May 27th. JonesTrading lowered their target price on shares of ProQR Therapeutics from $11.00 to $10.00 and set a “buy” rating for the company in a report on Friday, June 26th. Weiss Ratings downgraded shares of ProQR Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, June 23rd. Finally, Wall Street Zen cut shares of ProQR Therapeutics from a “hold” rating to a “strong sell” rating in a report on Saturday, May 16th. Four investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $7.33.

Institutional Investors Weigh In On ProQR Therapeutics

A number of hedge funds have recently made changes to their positions in the business. Jane Street Group LLC grew its position in ProQR Therapeutics by 699.3% during the first quarter. Jane Street Group LLC now owns 91,120 shares of the biopharmaceutical company’s stock valued at $121,000 after buying an additional 79,720 shares during the period. Bank of America Corp DE raised its position in ProQR Therapeutics by 25.7% in the second quarter. Bank of America Corp DE now owns 119,198 shares of the biopharmaceutical company’s stock worth $243,000 after acquiring an additional 24,347 shares during the period. BNP Paribas Financial Markets raised its position in ProQR Therapeutics by 28.4% in the second quarter. BNP Paribas Financial Markets now owns 121,494 shares of the biopharmaceutical company’s stock worth $248,000 after acquiring an additional 26,893 shares during the period. Osaic Holdings Inc. boosted its stake in ProQR Therapeutics by 59.6% in the second quarter. Osaic Holdings Inc. now owns 12,050 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 4,500 shares during the last quarter. Finally, Two Sigma Investments LP boosted its stake in ProQR Therapeutics by 86.3% in the third quarter. Two Sigma Investments LP now owns 417,300 shares of the biopharmaceutical company’s stock valued at $889,000 after acquiring an additional 193,260 shares during the last quarter. 32.65% of the stock is currently owned by institutional investors.

About ProQR Therapeutics

ProQR Therapeutics N.V. is a clinical-stage biotechnology company dedicated to developing RNA-based therapies for severe genetic diseases. Utilizing its proprietary Axiomer® RNA editing platform, ProQR aims to correct disease-causing mutations directly at the messenger RNA level. The company’s pipeline features several investigational candidates, including sepofarsen (formerly QR-110) for Leber congenital amaurosis type 10, QR-421a targeting Usher syndrome and certain forms of retinitis pigmentosa, and QR-313 for dystrophic epidermolysis bullosa.

Founded in 2012 and headquartered in Leiden, the Netherlands, ProQR maintains a significant presence in Cambridge, Massachusetts, to support its clinical research and regulatory initiatives.